Related Experiment Video
Updated: Aug 25, 2026

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Ethinylestradiol/chlormadinone acetate
Monique P Curran1, Antona J Wagstaff
1Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
Abstract:
Ethinylestradiol/chlormadinone acetate 0.03/2mg (EE/CMA) is a combined monophasic contraceptive pill with antiandrogenic properties. In a large, noncomparative, multicentre trial (< or =24 cycles of treatment per woman) and two (6- and 12-cycle) postmarketing surveillance studies, EE/CMA was effective in preventing pregnancy. EE/CMA was significantly more effective than EE/levonorgestrel 0.03/0.15 mg/day in treating women with mild-to-moderate papulopustular acne of the face and related disorders in a randomised, single-blind, multicentre trial. EE/CMA was well tolerated in clinical trials and the postmarketing surveillance studies. Adverse events were those commonly reported with oral contraceptives. As expected, the most common menstrual disturbances were breakthrough bleeding, spotting and amenorrhoea.
More Related Videos
Related Concept Videos
Intrauterine Drug Delivery Systems
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Birth Control Methods
Cholinergic Antagonists: Pharmacokinetics
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

